Lipid peroxidation and paraoxonase activity in nocturnal cyclic and sustained intermittent hypoxia

Okur, Hacer Kuzu; Pelin, Zerrin; Yüksel, Meral; Yosunkaya, Şebnem

doi:10.1007/s11325-012-0703-5

Cited by 19 publications

(21 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…. In accordance with the previous studies and based on our data, we conclude that the systemic high oxidative stress in OSA increases protein oxidation to some extent as indicated by significantly higher AOPP levels .…”

Section: Discussionsupporting

confidence: 93%

Advanced oxidation protein products and ischaemia‐modified albumin in obstructive sleep apnea

Özben

Huseyinoglu

Hanikoglu

et al. 2014

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Advanced oxidation protein products and ischaemia‐modified albumin in obstructive sleep apnea

Özben

Huseyinoglu

Hanikoglu

et al. 2014

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…In addition to our research, Kuzu Okur and colleagues noted significantly lower levels of PON1 in COPD patients compared with controls. 103 Torres-Ramos and coworkers related COPD to CVD by pointing out significantly decreased PON1 activity in more severe forms of COPD and its inverse association with the concentration of lipid hydroperoxides. 104 Moreover, it has been found that genotype distribution of PON1 Q192R gene polymorphism differed significantly between COPD patients and controls with frequency of the QQ phenotype being higher and while the RR phenotype was absent in controls.…”

Section: Pon1 and Renal Diseasementioning

confidence: 99%

Paraoxonase 1 and atherosclerosis‐related diseases

et al. 2019

View full text Add to dashboard Cite

A direct and an indirect relationship between paraoxonase 1 (PON1) and atherosclerosis exists. Given PON1's physical location within high‐density lipoprotein (HDL) particles and its recognized enzyme activity, it is certainly reasonable to suggest that PON1 facilitates the antiatherogenic nature of HDL particles. PON1 also plays a role in regulating reverse cholesterol transport, antioxidative, anti‐inflammatory, antiapoptotic, vasodilative, and antithrombotic activities and several endothelial cell functions. HDL dysfunctionality is a more recent issue and seems to be centered on pathological conditions affecting HDL structure and size profiles. This review is focused on the role of PON1 status in different atherosclerosis‐related diseases that we have studied over the last twenty years (coronary heart disease, acute ischemic stroke, diabetes mellitus type 2, end‐stage renal disease, chronic obstructive pulmonary disease, and sarcoidosis) with the aim to determine the true value of PON1 as a biomarker. The role of PON1 in cancer is also covered, as risk factors and mechanisms underlying both atherosclerosis and cancer share common features.

show abstract

“…Several studies reported perturbation in oxidative and antioxidant balance in patients with OSA [14,15]. There are several reports on PON activities in OSA patients; however, the results are inconsistent [16,17]. Therefore, the present study aimed to reassess the published studies on PON activity in OSA patients compared with controls.…”

Section: Introductionmentioning

confidence: 91%

“…A total of 5 studies including 131 OSA patients and 93 controls were included in the meta-analysis [16,[19][20][21][22]. All studies had reported PON activity, while two studies had reported ARE activity, and no study had reported LAC activity.…”

Section: Characteristics Of Eligible Studiesmentioning

confidence: 99%

Paraoxonase Activity in Patients with Obstructive Sleep Apnea: a Systematic Review and Meta-analysis

Fadaei

Safari‐Faramani

Rezaei

et al. 2019

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Obstructive sleep apnea (OSA) is a common sleep disorder affecting high proportion of the population. This disorder is associated with an increase in the oxidative stress and cardiovascular disease. Paraoxonase (PON) is a lipolactonase enzyme removing toxic lipids and decreasing lipoprotein oxidation. The present study was conducted to reassess possible alternation of PON activities in OSA patients. Studies measured PON activities in OSA were searched in PubMed, Scopus, EMBASE, Web of Science databases, and Cochrane Library from January 1990 to February 2019. Screening of the studies was performed by two authors independently according to title, abstract, and full text. Quality of studies was assessed by Newcastle-Ottawa Quality Assessment Scale, and random-effect model was used for evaluating the effect of OSA on PON activities. A total of 97 records were found in searching, 39 duplicated records were removed, and 5 studies for PON activity and 2 studies for aryl-esterase (ARE) activity were included in the meta-analysis. Pooled analysis showed no significant difference in terms of PON activity between OSA and control groups (p = 0.434). Similarly, ARE demonstrated no significant difference between OSA and control groups (p = 0.515). Subgroup meta-analysis according to age, BMI, AHI, and diagnosis criteria demonstrated no significant difference between two groups. The results of this study indicated no association between OSA and PON activities as an antioxidant enzyme. However, a relatively low number of studies limited us to conclude a definite conclusion; therefore, more studies are needed in this regard.

show abstract

Lipid peroxidation and paraoxonase activity in nocturnal cyclic and sustained intermittent hypoxia

Abstract: The results of this study revealed that both OSA and non-apneic, nocturnal desaturated COPD patients showed increased levels of lipid peroxidation and decreased PON activity despite the differences in nocturnal hypoxia pattern.

Cited by 19 publications

References 47 publications

Advanced oxidation protein products and ischaemia‐modified albumin in obstructive sleep apnea

Advanced oxidation protein products and ischaemia‐modified albumin in obstructive sleep apnea

Paraoxonase 1 and atherosclerosis‐related diseases

Paraoxonase Activity in Patients with Obstructive Sleep Apnea: a Systematic Review and Meta-analysis

Contact Info

Product

Resources

About